Source: Annual Congress 2009 - Epidemiology of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Dahl, B. Nordestgaard (Herlev, Denmark). Markers of early disease and prognosis in COPD. Eur Respir J 2009; 34: Suppl. 53, 1452

Member's Comments

No comment yet.

Related content which might interest you: Exercise desaturation in patients with COPD – potent  marker for more severe disease progression and prognosis Source: International Congress 2017 – Exercise testing in cardiorespiratory diseases Year: 2017 Delay in diagnosis of COPD leading to poor prognosis of disease Source: International Congress 2015 – Different data in COPD Year: 2015 Lung function reversibility as a predictor of disease progression in COPD Source: International Congress 2017 – Markers of COPD progression Year: 2017 Can HSP27 and HSP70 be used as biomarkers for chronic obstructive pulmonary disease diagnosis? Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Predictors of progression and risk of unfavorable outcome of chronic obstructive pulmonary disease Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system Year: 2015 Cardiovascular risk, subclinical atherosclerosis and markers of systemic inflammation in patients with COPD and frequent exacerbator phenotype Source: International Congress 2016 – Monitoring comorbidities Year: 2016 Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 Identification of oxidative stress markers and their association with inflammation in smokers and early chronic obstructive pulmonary disease (COPD) Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 The evaluation of disease severity/staging for prognosis Source: Eur Respir Monogr 2016; 71: 97-105 Year: 2016 Time to move from prognostication to diagnosis and treatment of heart disease in acute exacerbation of COPD Source: Eur Respir J, 49 (6) 1700912; 10.1183/13993003.00912-2017 Year: 2017 Knowledge of prognosis of chronic obstructive pulmonary disease (COPD) patients and their families in the last year of life Source: Eur Respir J 2002; 20: Suppl. 38, 205s Year: 2002 Dynapenia in COPD exacerbation: what is its relevance in clinical prognosis? Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy Year: 2017 Which markers other than FEV1 reflect disease progression in COPD? Source: Eur Respir J 2004; 24: Suppl. 48, 45s Year: 2004 Biomarkers in the management of COPD Source: Eur Respir Rev 2009; 18: 96-104 Year: 2009 Factors associated with poor prognostic outcome in acute exacerbation of COPD Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Markers of ageing in the limb muscle of patients with COPD Source: International Congress 2015 – Translational research in respiratory care: new findings Year: 2015 The most frequent comorbidies in COPD and their inflence on the prognosis of the disease Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Functional status in patients with chronic lung disease Source: Eur Respir J 2007; 30: Suppl. 51, 652s Year: 2007